Evidence map›Paper›PMID 33523302›Full record

ArticleEuropean journal of pediatrics2021

Live attenuated vaccines under immunosuppressive agents or biological agents: survey and clinical data from Japan.

Koichi Kamei, Isao Miyairi, Kensuke Shoji, Katsuhiro Arai, Toshinao Kawai, Masao Ogura, Kenji Ishikura, Mayumi Sako, Hidefumi Nakamura

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Clinical microbiology reviews · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Koichi KameiDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. kamei-k@ncchd.go.jp.ORCID https://orcid.org/0000-0003-3528-6961
Isao MiyairiDivision of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Kensuke ShojiDivision of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan.
Katsuhiro AraiDivision of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
Toshinao KawaiDivision of Immunology, National Center for Child Health and Development, Tokyo, Japan.
Masao OguraDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Kenji IshikuraDivision of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
Mayumi SakoDivision for Clinical Trials, Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
Hidefumi NakamuraDepartment of Development Strategy, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.
National Center For Child Health and Development · JP

Funding

grants from the National Center for Child Health and Development 30-7the Japan Foundation for Pediatric Research 17-004
6 · The paper itself

Abstract

Live attenuated vaccines are contraindicated for patients on immunosuppressive agents or biological agent, except for live attenuated varicella vaccine, although previous reports showed their effectiveness and safety. This study is the nationwide cross-sectional research about the current utilization of live attenuated vaccines for patients on immunosuppressive agents or biological agents in Japan. We sent questionnaires to pediatric centers and examined whether each institution offered live attenuated vaccines to patients with immunosuppressive agents or biological agents (institutional research). We also examined adverse events associated with live attenuated vaccines between 2013 and 2017 (patient research). In the institutional research, 46 out of 334 institutions (13.8%) administered live attenuated vaccines to patients receiving immunosuppressive agents. In contrast, only six out of 270 institutions (2.2%) administered live attenuated vaccines to patients receiving biological agents. However, 66.3% of physicians answered that patients receiving immunosuppressive agents should be immunized with live attenuated vaccines, and only 7.0% disagreed with them. In the patient research, data for 781 patients were collected. Vaccine-associated infections were observed in only two patients (0.3%), both of whom had varicella, although they recovered promptly. No life-threatening adverse events were noted.

conclusionIn pediatric centers, the demand for live attenuated vaccines in patients receiving immunosuppressive agents was high and most physicians think they should be immunized. Immunization with live attenuated vaccines appeared safe in patients receiving immunosuppressive agents, although further studies are needed for patients receiving biological agents What is known: • Live attenuated vaccines (LAV) are generally contraindicated for patients on immunosuppressive agents (IS) or biological agents (BA), except for live attenuated varicella vaccine, as immunocompromised patients are at greater risk for serious viral infection from the vaccine strains. • Viral infections, such as measles and varicella, cause serious complications in children receiving IS. • Several previous reports showed that LAV is relatively effective and safe for patients receiving IS. What is new: • In Japan, the demand for LAV in patients receiving IS was high, and most physicians hoped they should be immunized. • Vaccine-associated infection is rarely observed in patients with IS after LAV administration. • Immunization with LAV appeared safe in patients receiving IS.

trial registrationUniversity Hospital Medical Information Network (UMIN). TRIAL REGISTRATION NUMBER: UMIN000029176.Date of registration: 2017/09/19.

Indexed as

Biological FactorsImmunosuppressive AgentsChildCross-Sectional StudiesHumansJapanMeasles-Mumps-Rubella VaccineSurveys and QuestionnairesVaccines, AttenuatedBiological FactorsImmunosuppressive AgentsMeasles-Mumps-Rubella VaccineVaccines, AttenuatedAdverse eventsInstitutional researchNationwide studyPatient researchQuestionnairesVaccine-strain infectionsVaricella

Identifiers

PMID33523302
OpenAlexW3129066338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.